Ads
related to: cetuximab fda approval history- Clinical Study Results
View Clinical Study Results
& Efficacy Info For IMFINZI.
- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Recommended Dosing
Determine The Appropriate Dosing
For A Patient On IMFINZI.
- Order Brochures Here
Download An Instructional Brochure
On Ordering IMFINZI For Patients.
- Download Resources
Find IMFINZI Dosing Brochures, FAQs
& More In The Resource Library.
- Physician Resources
Find Programs & Support Resources
To Share With Your IMFINZI Patients
- Clinical Study Results
Search results
Results From The WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
The FDA approved the aforementioned colorectal cancer drug, Erbitux, on February 12, 2004. In May 2001, while ImClone was still seeking approval for the drug (then known as IMC-C225), the CBS news program "60 Minutes" aired a story about two cancer patients' struggles to obtain "compassionate use" of the drug. One ultimately succeeded; the ...
Krazati had received accelerated approval from the FDA in 2022 for the treatment of a type of advanced lung cancer with the mutated form of the gene known as KRAS.
Hepion Pharmaceuticals (NASDAQ: HEPA) is one of the sponsors for the Benzinga Biotech Global Small Cap Conference taking place on March 24-25, 2021. The information contained in this article in no ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
The U.S. Food and Drug Administration (FDA) approved the drug for use in acute pain, but Vertex aims to eventually win approval in chronic pain, too. Clinical trials are ongoing, ...
Nimotuzumab (h-R3, [2] BIOMAb EGFR, Biocon, India; [3] TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was ...
Ads
related to: cetuximab fda approval history